Trials / Completed
CompletedNCT03829852
Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients
Investigate the Real-life Treatment Outcome of Regorafenib in Treating mCRC Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 716 (actual)
- Sponsor
- Taipei Veterans General Hospital, Taiwan · Other Government
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Regorafenib is currently the standard of care for refractory mCRC patients. Pivotal studies of regorafenib have proven the efficacy and safety, with a 28-day cycle (21 days on, 7 days off) and 160 mg dose given once daily. In the clinic, patients often have some complicated condition. This study aims to perform retrospective medical chart review of mCRC patients who received regorafenib treatment in two medical centers in Taiwan to examine treatment effectiveness in the routine clinical practice setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib | Treatment was performed based on physician's discretion |
Timeline
- Start date
- 2019-02-11
- Primary completion
- 2020-12-08
- Completion
- 2020-12-08
- First posted
- 2019-02-04
- Last updated
- 2021-07-23
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT03829852. Inclusion in this directory is not an endorsement.